Tesamorelin ���景与作用机制 — Quick Reference

By Editorial Desk · published 2026-04-28 · last reviewed 2026-05-28 · Faq

This is a working overview of 生长激素轴, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-28. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

Molecular Background and Receptor Mechanism

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.

Tesamorelin at a glance

Background and Clinical Profile

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Related pages on this site

• Efficient collection
• Sustainable checklist
• Lightweight trends
• Technical collection
• Optimized checklist
• Seasonal notes
• Comprehensive collection
• Modern collection

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Reference notes

The 2019 Indian general election in Jammu and Kashmir was held for 6 seats in the state. The voting process was held in five phases on 11, 18, 23, 29 April and 6 May 2019.The Bharatiya Janata Party and the Jammu and Kashmir National Conference won 3 seats each with the BJP getting an impressive 46.4% votes hare. JKNC's vote share was 7.9%. This was the last general election before the state's special status was revoked and later that same year the state was reconstituted into two union territories.

The Sumerians are said to have cultivated and harvested the opium poppy (Papaver somniferum) in lower Mesopotamia as early as 3400 BC, though this has been disputed. The most ancient testimony concerning the opium poppy found to date was inscribed in cuneiform script on a small white clay tablet at the end of the third millennium BC. This tablet was discovered in 1954 during excavations at Nippur, and is currently kept at the University of Pennsylvania Museum of Archaeology and Anthropology. Deciphered by Samuel Noah Kramer and Martin Leve, it is considered to be the most ancient pharmacopoeia in existence. Some Sumerian tablets of this era have an ideogram inscribed upon them, "hul gil", which translates to "plant of joy", believed by some authors to refer to opium. The term gil is still used for opium in certain parts of the world. The Sumerian goddess Nidaba is often depicted with poppies growing out of her shoulders. About 2225 BC, the Sumerian territory became a part of the Babylonian empire. Knowledge and use of the opium poppy and its euphoric effects thus passed to the Babylonians, who expanded their empire eastwards to Persia and westwards to Egypt, thereby extending its range to these civilizations. British archaeologist and cuneiformist Reginald Campbell Thompson writes that opium was known to the Assyrians in the 7th century BC. The term "Arat Pa Pa" occurs in the Assyrian Herbal, a collection of inscribed Assyrian tablets dated to c. 650 BC.

== Tissue Localization == Prepro-URP which is the precursor to the mature URP peptide is found in various tissues including specific parts of the brain such as frontal lobe and hypothalamus, and other peripheral tissues such as heart, kidneys, lungs, placenta, ovaries, and testes. In humans the amount of UII and URP gene expression are comparable except in the spinal cord where UII gene expression is much higher. In rats the UII gene expression is higher than the URP gene expression throughout the entire body. However, when the brains of the rats were tested, only the URP peptide was found making it the primary endogenous ligand in the brain. Unlike humans and rats, URP gene expression is found in mice spinal cords.

==== Affixes ==== Prefixes and suffixes, primarily in Greek—but also in Latin, have a droppable -o-. As a general rule, this vowel almost always acts as a joint-stem to connect two consonantal roots (e.g. arthr- + -o- + -logy = arthrology), but generally, the -o- is dropped when connecting to a vowel-stem (e.g. arthr- + -itis = arthritis, instead of arthr-o-itis). Generally, Greek prefixes go with Greek suffixes and Latin prefixes with Latin suffixes. Although it is technically considered acceptable to create hybrid words, it is strongly preferred in coining new terms not to mix different lingual roots. Examples of accepted medical words that do mix lingual roots are neonatology and quadriplegia. Prefixes do not normally require further modification to be added to a word root because the prefix normally ends in a vowel or vowel sound, although in some cases they may assimilate slightly and an in- may change to im- or syn- to sym-. Suffixes are attached to the end of a word root to add meaning such as condition, disease process, or procedure. Suffixes are categorized as either (1) needing the combining form, or (2) not needing the combining form since they start with a vowel.

==== Stretched ==== Neither age or size of the flaccid penis accurately predicted erectile length. Stretched length has correlated with erect length in some cases. However, studies have also shown drastic differences between stretched and erect length. One study found that a minimal tension force of approximately 450 g during stretching of the penis was required to reach a full potential erection length. This study also found that tension forces exerted in this study by the urologist were shown to be significantly (P<0.01) lower than 450g. This may account for differences between stretched and erect length.

Sources: en.wikipedia.org

Reference notes

The first Volunteer unit to be sent out was a 1,300 man composite battalion group, composed of infantry recruited from across London units and a field battery from the Honourable Artillery Company, the City Imperial Volunteers, which was raised in early January 1900; it was sent into combat after six weeks of training in South Africa, where Lord Roberts described it as "quite excellent", and was returned home in October. At the same time, a number of service companies were raised from volunteer units, employed as integral companies of their sister regular battalions, and were well regarded in the field. The decision was taken in late December to form a new force, the Imperial Yeomanry, to consist of mounted infantry. Whilst the Yeomanry provided many of the officers and NCOs, only a small number of the junior ranks came from existing Yeomanry regiments, with some more from Volunteer corps. The units performed well, but recruiting proceeded in fits and starts—recruitment stopped in May, and was only resumed in early 1901—and so an adequate supply of manpower was not always available. Sixty militia battalions, around 46,000 men, also volunteered and were eventually sent to South Africa. They were employed mainly on lines of communication, and regarded as second-line troops of low quality; this was unsurprising, as they were strongly deficient in officers, heavily composed of men of 18 and 19, who were regarded as too young by the Regular Army, with many of their best and most experienced men already deployed with regular units as members of the Militia Reserve.

Alcohol dehydrogenase class-3 is an enzyme that in humans is encoded by the ADH5 gene. This gene encodes glutathione-dependent formaldehyde dehydrogenase or the class III alcohol dehydrogenase chi subunit, which is a member of the alcohol dehydrogenase family. Members of this family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. Class III alcohol dehydrogenase is a homodimer composed of 2 chi subunits. It has virtually no activity for ethanol oxidation, but exhibits high activity for oxidation of long-chain primary alcohols and for oxidation of S-hydroxymethyl-glutathione, a spontaneous adduct between formaldehyde and glutathione. This enzyme is an important component of cellular metabolism for the elimination of formaldehyde, a potent irritant and sensitizing agent that causes lacrymation, rhinitis, pharyngitis, and contact dermatitis.

The MNPs may puncture the skin surface, enabling rapid onset of drug bypassing directly into the dermal capillaries. Pain-free. Can be localized to provide direct access to the intended tissues. Less dependent on skilled medical workers, as MNPs can be administered safely by the patient themself. Some drugs have poor solubility in water, with MNPs insoluble drugs and compounds can be directly "injected" to the dermal layer. Further enhancing the transdermal delivery of insoluble drugs. Better safety compared to needle and syringe method (needlestick). Less waste, eliminate pathogen transmission, and injuries. At least 300,000 needlestick related injuries occurred in the US annually, with disposal contributing to almost half of the injuries.

{\displaystyle {\hat {H}}=\hbar \omega _{+}\left({\hat {a}}_{+}^{\dagger }{\hat {a}}_{+}+{\frac {1}{2}}\right)-\hbar \omega _{-}\left({\hat {a}}_{-}^{\dagger }{\hat {a}}_{-}+{\frac {1}{2}}\right)+\hbar \omega _{z}\left({\hat {a}}_{z}^{\dagger }{\hat {a}}_{z}+{\frac {1}{2}}\right)}

Sources: en.wikipedia.org

Frequently asked questions